MAXCYTE, INC. 8-K

What Happened MaxCyte, Inc. (MXCT) filed an 8-K on June 16, 2026 reporting that Nasdaq has notified the company it has regained compliance with the $1.00 minimum closing bid-price requirement for continued listing on the Nasdaq Global Select Market (Nasdaq Listing Rule 5450(a)(1)). The company had previously received a notice on March 16, 2026 that its closing bid had fallen below $1.00 for 30 consecutive trading days. Nasdaq’s June 10, 2026 letter confirmed the closing bid was $1.00 or greater for the 10 consecutive business days from May 27, 2026 to June 9, 2026, and the matter is now closed.

Key Details

• Initial Nasdaq non-compliance notice received March 16, 2026; previously disclosed in an 8-K filed March 20, 2026.
• Nasdaq determination letter dated June 10, 2026 found closing bid ≥ $1.00 for May 27–June 9, 2026 (10 consecutive business days).
• Regained compliance with Nasdaq Listing Rule 5450(a)(1) for the Global Select Market; Nasdaq closed the matter.
• The 8-K was signed by Parmeet Ahuja, Chief Financial Officer, and filed June 16, 2026.

Why It Matters Regaining compliance means MaxCyte’s common stock remains listed on the Nasdaq Global Select Market and avoids potential delisting procedures tied to the bid-price rule. For investors, this preserves trading continuity and access to a major exchange, which can affect liquidity and market visibility. The filing is a factual update; it does not provide financial results or other operational changes.